Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers
Latest Information Update: 12 Mar 2026
At a glance
- Drugs Curcumin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
Most Recent Events
- 27 Feb 2026 Actual primary completion date changed from 4 Mar 2025 to 29 May 2025.
- 19 Sep 2025 Actual primary completion date changed from 6 Jun 2025 to 4 Mar 2025.
- 23 May 2025 Planned End Date changed from 1 Aug 2025 to 1 May 2026.